MedTrace Logo

CD36 in Nutrient Delivery and Its Dysfunction

NCT03012386 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2022-11-30

Study results available
· View outcomes & findings →

Summary

This proposal will test the hypothesis that chronic treatment with sildenafil with and without the use of nitric oxide substrate, L-arginine, protects against fatty acid induced impairment of endothelial function, improves insulin-stimulated microvascular recruitment, insulin sensitivity and glucose uptake in CD36 rs3211938 G-allele carriers.

Conditions

Interventions

DRUG

Sildenafil Citrate in G allele carrier

chronic use of phosphodiesterase 5 inhibitor in G allele carrier

DRUG

Sildenafil Citrate in non G allele carrier

chronic use of phosphodiesterase 5 inhibitor in Non G allele carrier

Sponsors & Collaborators

  • Washington University School of Medicine

    collaborator OTHER

  • Vanderbilt University Medical Center

    lead OTHER

Principal Investigators

  • Cyndya Shibao, MD · Vanderbilt University Medical Center

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2021-07-31
Completion
2021-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03012386 on ClinicalTrials.gov